Victoria G. Manax, MD
Chief Medical Officer
Pancreatic Cancer Action Network
Dr. Victoria Manax is the Chief Medical Officer of the Pancreatic Cancer Action Network. She provides strategic direction and operational oversight to the organization’s high-priority clinical initiatives, with emphasis on the Precision Promise initiative and its Clinical Trial Consortium. She works closely with clinical cancer research institutions and biopharmaceutical companies to build a productive and collaborative team that will accelerate progress toward the goal to double pancreatic cancer survival by 2020. Dr. Manax joined the Pancreatic Cancer Action Network in 2016 from Celgene Corporation, most recently serving as their executive medical director and gastrointestinal therapeutic lead in U.S. Medical Affairs.
Manax received her M.B. BCh B.A.O (MD equivalent) from University College Dublin. She completed her medical training at St. Vincent’s University Hospital in Dublin and University Hospital Galway. Following her training in Ireland, she embarked on a career in the biotech industry at Abraxis Bioscience. She joined the Celgene team in 2010 to focus on the solid tumor program. Manax was involved in the development and approval of the drug Abraxane for multiple indications and served as the global medical lead for the launch of Abraxane in pancreatic cancer.
The Dallas Business Journal named Manax as one of the leading individuals in “40 Under 40” in 2010 and as part of “Who’s Who in Healthcare” in 2013.